Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals has acquired the commercial rights to nabilone in the UK and other European markets from Cambridge Laboratories for $14 million.
Subscribe to our email newsletter
Valeant markets nabilone in the US and Canada under the brand name Cesamet. Nabilone is indicated for use in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatments.
“There remains a need for cannabinoids like Cesamet for patients who have exhausted conventional treatments and whose quality of life continues to be adversely impacted by the debilitating side effects of cancer chemotherapy,” said Timothy Tyson, Valeant’s president and CEO.
Valeant acquired Cesamet from Eli Lilly & Company in 2000. Nabilone is the only licensed cannabinoid in the UK.